- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Impact of Hypophosphatemia
Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.
EP: 1.Background and Causes of Iron Deficiency Anemia
EP: 2.Pathophysiology of Iron Deficiency Anemia
EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia
EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia
EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis
EP: 6.Oral vs IV Iron in Clinical Practice
EP: 7.FDA-Approved IV Iron Formulations
EP: 8.Factoring in Safety Considerations With IV Iron Products
EP: 9.Adverse Effects Associated With Hypophosphatemia
EP: 10.Clinical Impact of Hypophosphatemia
EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron
EP: 12.Adherence and Time Spent Receiving IV Iron Infusions
EP: 13.Step Edits Associated with IV Iron Therapies
EP: 14.The Future of IV Iron Administration
EP: 15.Closing Thoughts on Iron Deficiency Anemia
Video content above is prompted by the following:
- Considering the incidence of hypophosphatemia in patients with IDA was significantly lower with the use of FDI and FXT than with FCM therapy, how does this impact the choice of treatment?
- How do you monitor phosphate levels?
- A retrospective analysis found a significantly higher combined event rate of fracture, radiological signs of osteomalacia, and kidney stones among patients treated with FCM than after ferric derisomaltose (FDI) treatment. Do these results impact your clinical decision-making?
- What potential interventions or preventative measures could be taken to mitigate the risk of hypophosphatemia in patients receiving IV iron formulations?
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
